EXOME

all the information, none of the junk | biotech • healthcare • life sciences

And Then There Were 3 at TorreyPines Therapeutics

Xconomy San Diego — 

TorreyPines Therapeutics (Nasdaq: TPTX) says it has reduced its workforce to just three employees—the CEO, CFO, and Vice President/General Counsel. In September 2008 the company said it had 13 employees, which was down from more than 40 at the beginning of last year. The company, which was known as Neurogenetics until 2005, is focused on developing treatments for migraines. TorreyPines sold its Alzheimer’s research program to partner Eisai Co. four months ago.